Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Mol Psychiatry
; 27(4): 1898-1907, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1612180
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of prophylactic and therapeutic drugs for persons infected with the virus. Drug repurposing for the COVID-19 pandemic has received particular attention. Increasing clinical data suggest that antidepressant use in early-stage subjects with COVID-19 might be associated with a reduced risk of intubation or death. Among the antidepressants, fluvoxamine is the most attractive drug for mild to moderate subjects with COVID-19. In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19. Furthermore, we discuss a possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders (i.e., autism spectrum disorder and schizophrenia) in offspring.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Autism Spectrum Disorder
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Mol Psychiatry
Journal subject:
Molecular Biology
/
Psychiatry
Year:
2022
Document Type:
Article
Affiliation country:
S41380-021-01432-3
Similar
MEDLINE
...
LILACS
LIS